Sitawar-DM Forte

Sitawar-DM Forte (Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin HCl 1000 mg) is a balanced triple therapy formulated with Sitagliptin 100 mg, Dapagliflozin 10 mg, and Metformin HCl 1000 mg for the effective management of Type 2 Diabetes Mellitus. This triple-combination medication (sitagliptin 100 mg, dapagliflozin 10 mg, and metformin 1000 mg) is used to improve glycemic control in adults with type 2 diabetes. It works by enhancing insulin release (sitagliptin), increasing urinary glucose excretion (dapagliflozin), and lowering liver glucose production (metformin), often as an adjunct to diet and exercise. Together, the combination supports better fasting and postprandial blood sugar control as part of an overall diabetes management plan.

How Does Sitawar-DM Forte (Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin HCl 1000 mg) Work?

• Sitagliptin (100 mg) - DPP-4 Inhibitor: Inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme, increasing levels of active incretin hormones (GLP-1 and GIP). This causes a glucose-dependent increase in insulin release and a decrease in glucagon levels.
• Dapagliflozin (10 mg)—SGLT2 Inhibitor: Inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption into the bloodstream. This leads to increased glucose excretion through urine (glycosuria), reducing overall blood glucose independent of insulin action.
• Metformin HCl (1000 mg) - Biguanide: Lowers blood glucose by decreasing hepatic glucose production (gluconeogenesis), decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake. 

The triple-action approach helps provide comprehensive glycemic control through complementary mechanisms. Regular therapy along with diet and exercise supports long-term diabetes management and metabolic balance.

Clinical Benefits

• Helps support effective control of fasting and post-meal blood sugar levels.
• Supports improvement in overall glycemic management in adults with type 2 diabetes mellitus.
• Helps improve insulin utilization and glucose regulation through multiple mechanisms.
• Dapagliflozin supports urinary glucose excretion, contributing to better glycemic balance.
• Metformin helps improve insulin sensitivity and supports reduction in hepatic glucose production.
• May help support long-term HbA1c management when used along with lifestyle modifications.
• Fixed-dose triple therapy offers treatment convenience and may help improve patient compliance.

Dosage & Administration

Sitawar-DM Forte (Sitagliptin 100 mg + Dapagliflozin 10 mg + Metformin HCl 1000 mg) should be taken under medical supervision and as directed by the physician. The dosage may vary depending on the patient’s blood glucose levels, kidney function, clinical condition, and therapeutic response. Patients are advised to continue regular blood sugar monitoring, maintain a balanced diet, and follow recommended lifestyle modifications during treatment.

Disclaimer

To be used under medical supervision only. The information provided is for educational purposes and should not replace professional medical advice, diagnosis, or treatment.